]>
IRCT20180103038199N11 IRCT 2022-02-09 Mashhad University of Medical Sciences Noscatem and COVID-19 Evaluation of the effectiveness of Noscatem herbal syrup on the clinical symptoms of outpatients with COVID-19 2022-02-20 anticipated 70 Complete https://irct.ir/trial/61438 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The volume of each block will be 4. Then write a list of blocks and assign numbers to them, for example (AABB (1) - BBAA (2) - BABA (3) - BAAB (4)) which according to the sample size of 140 people, we have 35 blocks. Then, random numbers between one and 35 are selected according to the Randomaize.com randomization site, and finally, the treatment allocation list is determined based on random numbers, Blinding description: Due to the use of a placebo similar to interventional therapy, the physician associated with the participants and participants will not be informed of the assigned treatment and also the analyst will be unaware of the treatment assigned to the two groups. Finally, after analyzing the data, the researcher who prepared the packages reveals codes A and B. 2-3 COVID-19 disease. Intervention 1: Intervention group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + Noscatem syrup (10 mg/5ml) prepared by Tamad Pharmaceutical Company three times a day and each time two tablespoons that is equivalent to 20 mg noscapine hydrochloride. Intervention 2: Control group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + placebo syrup three times a day, 2 tablespoons each time (placebo syrup prepared by Tamad Pharmaceutical Company). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Vahid Reza Askari
Faculty of medicine, Paradise of University, Vakil-Abad Blvd., Azadi Sq., Mashhad
Mashhad Iran (Islamic Republic of) 9177948564 +98 51 3800 2000 askariv@mums.ac.ir Mashhad University of Medical Sciences scientific Vahid Reza Askari
Faculty of medicine, Paradise of University, Vakil-Abad Blvd., Azadi Sq., Mashhad
Mashhad Iran (Islamic Republic of) 9177948564 +98 51 3800 2000 askariv@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Outpatients with COVID-19 Confirmed with RT-PCR SPO2 more than 90% Age between 18 to 60 years old 18 years 70 years Both Pregnant women Breastfeeding women U07.1 COVID-19 Treatment - Drugs Placebo Intervention group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + Noscatem syrup (10 mg/5ml) prepared by Tamad Pharmaceutical Company three times a day and each time two tablespoons that is equivalent to 20 mg noscapine hydrochloride Control group: receiving common treatments, including adult cold two tablets every eight hours, one tablespoon of diphenhydramine syrup every 8 hours, vitamin C 1000 mg effervescent + placebo syrup three times a day, 2 tablespoons each time (placebo syrup prepared by Tamad Pharmaceutical Company) Time to recover from illness based on questionnaire. Timepoint: before intervention and 3, 7 and 14 days after beginning the intervention. Method of measurement: questionnaire. Temad Pharmaceutical Company Approved 2021-09-07 Ethics committee of Mashhad University of Medical Sciences Deputy of Research and Technology of the University, Qurashi Building, Next to Hoveyzeh Cinema, University Street Mashhad Razavi Khorasan Iran (Islamic Republic of)